Legend Biotech’s Path to Profitability Gains Momentum with New Clinical Data

Legend Biotech Corp has taken a significant step toward its strategic goal of reaching operational profitability this calendar year. The company recently showcased extensive clinical data for its leading CAR-T cell therapy at the Tandem Meetings in the United States. This presentation comes as the firm celebrates a major milestone: treating over 10,000 patients with its therapy as of January 2026.

• Flagship Therapy: Ciltacabtagene Autoleucel (a CAR-T treatment)
• Treatment Milestone: More than 10,000 patients treated (January 2026)
• Annual Production Capacity: Expanded Raritan site can now serve up to 10,000 patients per year
• Financial Target: Operational profitability planned for fiscal year 2026
• Cash Position: Approximately $1.0 billion USD (as of Q3 2025 close)

A critical component of Legend Biotech's profitability roadmap is the successful scaling of its manufacturing infrastructure. The physical expansion of its production facility in Raritan, New Jersey, is now complete. This site has been established as one of the central cell therapy manufacturing hubs in the U.S.

The enhanced capacity is designed to supply therapy for up to 10,000 patients annually. Management views this scaled production as a key factor in reducing the high costs associated with personalized cell therapies, thereby creating the necessary foundation to achieve corporate-level profitability in 2026.

Comprehensive Data Supports Earlier-Line Treatment Ambitions

At the recent medical conference, the company presented six poster analyses on Ciltacabtagene Autoleucel. The data, drawn from the CARTITUDE clinical program, focused on real-world effectiveness, safety, and treatment outcomes.

Should investors sell immediately? Or is it worth buying Legend Biotech Corp?

Notable findings included long-term progression-free survival rates in multiple myeloma patients and analyses on the efficacy of bridging therapies. Further evaluations covered manufacturing quality and quality-of-life-adjusted survival following neurological events. These collective insights are intended to bolster the case for using the therapy in earlier phases of treatment, which would substantially expand the eligible patient population.

Solid Cash Reserves Provide Operational Runway

From a financial perspective, the company appears well-positioned for the coming quarters. Legend Biotech ended the third quarter of 2025 with a robust cash balance of about $1.0 billion USD. This strong liquidity position is expected to cover funding requirements well into 2026.

Consequently, the firm has the necessary flexibility to advance its international commercialization efforts without an immediate need to pursue new capital-raising activities. Investors are now looking ahead to mid-March 2026, when Legend Biotech will disclose its complete financial results for the full fiscal year 2025. Market attention will likely center on revenue growth rates in international markets and developmental progress for next-generation in-vivo pipeline candidates.